Mylan NV, a global generic and specialty pharmaceuticals company, has launched generic Harvoni tablets, used to treat Hepatitis C.
The generic medications will be distributed under the brand name 'MyHep LVIR' in India.
A generic drug is identical to a brand name drug in dosage form, safety, quality, and intended use. Although generic drugs are identical to their branded counterparts, they are usually sold at substantial discounts from the branded price.
‘Mylan NV has launched generic Harvoni tablets, used to treat Hepatitis C. The company offers patients the potential to be cured through a simplified single tablet, once- daily treatment regimen.’
"Mylan recognizes the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus," Mylan President Rajiv Malik says.
The generic version is an important addition to the company's growing Hepato Care segment in India. Malik adds that the company offers patients the potential to be cured through a transformative and simplified single tablet, once- daily treatment regimen.
The launch of the generic drug follows the launch of generic Sofosbuvir in India under the brand name MyHepTM in April, 2015.
In September 2014, Mylan entered into an agreement with Gilead that granted the former non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in as many as 101 developing countries, including India.